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REVIEW CURRENTOPINION Heart failure in persons living with HIV infection Copyright 
www.co-hivandaids.coma,b a,bPriscilla Y. Hsue and David D. WatersPurpose of review
To discuss presentation, pathophysiology, complications, and treatment of heart failure in persons living
with HIV (PLWHIV) in the antiretroviral therapy (ART) era.
Recent findings
Since the advent of effective ART and improved longevity, heart failure has become more chronic and
insidious and is often characterized by preserved ejection fraction, diastolic dysfunction, and left ventricular
(LV) hypertrophy. The mechanism underlying heart failure in the setting of HIV infection remains unknown.
A high burden of coronary risk factors is often present in PLWHIV, and clinical manifestations of coronary
disease appear at a younger age compared with uninfected persons. Heart failure is more common in the
year following myocardial infarction in HIV-infected compared with uninfected patients. Epidemiological
data suggest the incidence of atrial fibrillation in PLWHIV is increasing, likely due to advancing age and
increasing rates of LV hypertrophy in this population. The treatment of heart failure in PLWHIV is
extrapolated from treatment of uninfected patients, as clinical trials have not been done specifically in HIV.
Summary
Symptoms of heart failure or echocardiographic evidence of cardiomyopathy increase the risk of death in
PLWHIV. Additional studies are needed to ascertain if HIV-specific issues such as newer ART, chronic
inflammation/immune activation, illicit drug use, and early initiation of ART are implicated in heart failure
pathogenesis.
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Heart failure is common among persons living with
HIV (PLWHIV) infection and portends a poor prog-
nosis [1]. Heart failure in PLWHIV changed drasti-
cally with the advent of highly effective
antiretroviral therapy (ART) and is now much dif-
ferent among persons receiving or not receiving
ART, as summarized in Table 1. In the pre-ART
era, HIV-associated cardiomyopathy was expressed
as symptomatic, systolic dysfunction with left ven-
tricular (LV) dilatation and was seen almost exclu-
sively in patients with advanced HIV disease and
AIDS. This type of heart failure is still common in
geographic areas where ART is not widely available
(which will be covered in another article in this
series). The incidence of this type of HIV-associated
cardiomyopathy has decreased dramatically from
the pre-ART era, from 25.6 cases per 1000 person-
years to 3.9 cases, according to one recent review [1].
In contrast, in the current era, the diagnosis of
heart failure includes many more asymptomatic
PLWHIV, and often refers only to systolic or diastolic
dysfunctiondetectedbyechocardiography. Inarecent
cohort study of 98015 uninfected and HIV-infected© 2017 Wolters Kluwer veterans, 2636 heart failure events occurred over 7.1
years of follow-up [2
&&
]. Heart failure with preserved
ejection fraction (HFpEF) accounted for 34.6% of
these, borderline HFpEF accounted for 15.5%, heart
failure with reduced ejection fraction (HFrEF) for
37.1%, and heart failure of unknown type for
12.8%. Compared with uninfected veterans, HIV-
infected veterans had an increased risk of HFpEF [haz-
ard ratio 1.21; 95% confidence interval (CI) 1.03–
1.41], borderline HFpEF (hazard ratio 1.37; 95% CI
1.09–1.72), and HFrEF (hazard ratio 1.61; 95% CI
1.40–1.86). Higher viral loads and lower CD4 counts
were associated with heart failure in PLWHIV. These
dataprovide ahelpful current snapshotofheart failureHealth, Inc. All rights reserved.
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KEY POINTS
 Heart failure in PLWHIV changed drastically with the
advent of highly effective ART and is now much
different among persons receiving or not receiving ART.
 In the pre-ART era, HIV-associated cardiomyopathy was
expressed as symptomatic, systolic dysfunction with LV
dilatation and was seen almost exclusively in patients
with advanced HIV disease and AIDS; in contrast, in
the current era, the diagnosis of heart failure includes
many more asymptomatic PLWHIV and often refers only
to systolic or diastolic dysfunction detected
by echocardiography.
 Heart failure in PLWHIV who are receiving ART are
older and carry a high cardiovascular risk factor
burden, with high prevalence of hypertension, smoking,
dyslipidemia, diabetes, and the metabolic syndrome.
 In PLWHIV, ART itself has both adversely increased the
risk of heart failure as well as played an important role
in the prevention of heart failure; still patients with
cardiomyopathy and heart failure who have not
received ART should receive this intervention.
 Treatment recommendations for heart failure in PLWHIV
are based upon trials done in uninfected heart failure
patients; however, additional studies are needed to
ascertain if HIV-specific issues such as newer ART,
chronic inflammation/immune activation, illicit drug
use, and early initiation of ART are implicated in the
development of CHF in HIV.
Heart failure in persons living with HIV infection Hsue and Waterswith HIV but the mechanism underlying these find-
ings in HIV remain unknown.PATHOPHYSIOLOGY OF HEART FAILURE
IN PERSONS LIVING WITH HIV WITHOUT
ANTIRETROVIRAL THERAPY
The pathophysiology of HIV-associated cardiomy-
opathy is multifactorial, with proposed causes in-
cluding direct HIV infection of the myocardium Copyright © 2017 Wolters Kluwe
Table 1. Features of heart failure in persons living with HIV acco
Untreated PLWHIV
Prevalence Decreasing with increased ART availabil
Type of HF Mainly systolic
Cause HIVopportunistic infections, inflammato
and nutritional deficiencies
Time course Acute
Treatment ARTþ standard HF care
Prognosis Poor without ART
ART, antiretroviral therapy; CAD, coronary artery disease; EF, ejection fraction; HF, he
1746-630X Copyright  2017 Wolters Kluwer Health, Inc. All rights resewith or without myocarditis, coinfection with
other viruses such as Coxsackie virus B3 and cyto-
megalovirus, opportunistic infections, and nutri-
tional disorders. Infection of the heart with the
HIV causes impaired systolic function. HIV gene
products, such as tat, probably also contribute.
Proinflammatory cytokines such as tumor necrosis
factor and IL-1ß have also been shown to depress LV
systolic function. In sub-Saharan Africa and other
poor areas, nutritional deficiencies may contribute
to HIV-associated cardiomyopathy. Selenium defi-
ciency has been reported in PLWHIV and is associ-
ated with a cardiomyopathy in China termed
Keshan disease [1].LEFT VENTRICULAR HYPERTROPHY IN
PERSONS LIVING WITH HIV
LV hypertrophy is more common in HIV-infected
patients than in controls. In our study, HIV-infected
participants had amean 8g/m2 larger LVmass index
compared with controls (P¼0.001) [3]. Higher LV
mass index was independently associated with low-
er nadir CD4 T-cell count, suggesting that immuno-
deficiency might play a role in this process. After
adjustment for age and traditional risk factors, HIV
patients were 2.4 times more likely to have diastolic
dysfunction than controls. Overall, 50% of PLWHIV
had diastolic dysfunction compared with 29% of
uninfected controls.
Another study compared LV mass in patients
with and without HIV infection, and with and with-
out hypertension [4]. In normotensive and in hy-
pertensive patients, the HIV-infected group had
greater LV mass and more diastolic dysfunction
compared with uninfected controls. In older data
from the Framingham Study, electrocardiographic
evidence of LV hypertrophy was shown to be a
strong predictor of cardiovascular death [5]. In our
study of PLWHIV, diastolic dysfunction predicted
sudden cardiac death (SCD) (hazard ratio 14.8, 95%r Health, Inc. All rights reserved.
rding to treatment status
PLWHIV receiving ART
ity Increasing with improved survival of PLWHIV
More often HF with preserved EF
ry, CAD, LVH, or both
Chronic
Standard HF care
Similar to HF in persons without HIV
art failure; LVH, left ventricular hypertrophy; PLWHIV, persons living with HIV.
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Table 2. Cardiac MRI results in persons living with HIV
compared with uninfected controls
Cardiovascular disease in HIV infected personsCI 4.0–55.4, P<0.001), but not as strongly as de-
pressed ejection fraction [6].Control
patients,
n¼92
HIV-Infected
patients,
n¼103 P value
LVEDV indexed
(ml/m2)
7814 7614 0.39
LVESV indexed
(ml/m2)
227 258 0.02
LVEF (%) 725 686 <0.001
LV mass indexed
(g/m2)
5411 5811 0.02
Pericardial effusion 19 (21%) 58 (57%) <0.001
Late-gadolinium enhancement 15 (16%) 84 (83%) <0.001
LV, left ventricular; LVEDV, left ventricular end diastolic volume; LVEF, left
ventricular ejection fraction; LVESV, left ventricular end systolic volume.
Adapted from [11
&&
].PATHOPHYSIOLOGY OF HEART FAILURE
IN PERSONS LIVING WITH HIV RECEIVING
ANTIRETROVIRAL THERAPY
In contrast to heart failure occurring in PLWHIV not
receiving ART, in which the course of the disease
plays out over weeks or months, heart failure in
PLWHIV who are receiving ART covers a more pro-
longed course. These patients are older and carry a
high cardiovascular risk factor burden, with high
prevalence of hypertension, smoking, dyslipidemia,
diabetes, and the metabolic syndrome. High alcohol
consumption in some PLWHIV may also contribute
to heart failure. Similar to recent reports that more
than 40% of reported myocardial infarctions (MI) in
HIVareactuallyType II ordemand relatedasopposed
to true atherothromboticdisease [7], it is possible that
unrecognized alcohol abuse and/or cocaine or meth
abuse contributes to cardiomyopathy in HIV.
Some types of ART adversely affect glucose and
lipid metabolism and thus indirectly increase the
risk of heart failure. In addition, zidovudine (AZT), a
nucleoside reverse transcriptase inhibitor, causes a
dose-dependent skeletal and cardiac myopathy that
has been attributed to mitochondrial toxicity and
has the potential to impair LV function directly [1].
ART has been blamed for the otherwise unexplained
LV hypertrophy that is seen in PLWHIV.
On the other hand, ART plays an important role
in thepreventionof the typeofheart failuredescribed
above thatwas so common in thepre-ARTera. Recent
evidence also suggests that specific types of ART are
associated with a lower risk of developing heart fail-
ure. In a cohort of 21435 PLWHIV in the veterans
affairs system, 438 incident heart failure events oc-
curred over a median follow-up of 5.4 years. Heart
failure risk was markedly lower in current tenofovir
disoproxil fumarate (TDF) users (hazard ratio¼0.68;
95% CI 0.53–0.86) compared with never users [8
&
].
Speculation as to why TDF might reduce the risk of
heart failure includes the possibility that it improves
viral control and thus reduces inflammation, or that
itmight be related to the lipid-lowering effect of TDF.
Further studies are needed to confirm this beneficial
effect of TDF in heart failure.
Coronary artery disease is an important contrib-
utor to heart failure in PLWHIV, as it is in other
populations. Survivors of MI with HIV infection are
on average a decade younger compared with unin-
fected post-MI patients and thus have better short-
term survival, as age is such an important predictor of
mortality post-MI. However, in an age-matched and
sex-matched analysis from a large contemporary Copyright © 2017 Wolters Kluwer 
536 www.co-hivandaids.comFrench database, hospitalizations for heart failure
were more common during 1 year of follow-up in
HIV-infected comparedwith uninfected patients, 3.3
versus 1.4%, (P¼0.02) [9]. HIV status was an inde-
pendent predictor of heart failure in this post-MI
cohort. Significantly, newer biomarkers often used
in heart failure such as ST2 as well as markers of
fibrosis such as GDF-15 are higher among HIV-
infected individuals; in addition, these markers are
associated with structural abnormalities on echo and
are better predictors of mortality in HIV [10
&
].
Cardiac MRI provides insight into the subtle LV
abnormalities that contribute to heart failure in
PLWHIV. A recent study compared the results of
cardiac MRI between 103 PLWHIV without known
cardiovascular disease, mean age 4510 years, and
92 uninfected controls of a similar age [11
&&
]. As
shown in Table 2, LV ejection fraction, while still
in the normal range, was 6% lower and LV mass was
7% higher in the HIV-infected patients. A pericardial
effusion was present in more than half of the
PLWHIV, much more common than the frequency
in controls. Late-gadoliniumenhancement, amarker
of myocardial fibrosis was observed in 83% of HIV-
infected patients and 16% of uninfected controls.
Examples of an HIV-infected and a control patient
from this study are shown in Fig. 1. As fibrosis in the
general population is associated with SCD, whether
or not higher levels of myocardial fibrosis underlie
SCD in the setting of HIV remains unknown [12].ATRIAL FIBRILLATION IN PERSONS LIVING
WITH HIV
Advanced age and LV hypertrophy are strong risk
factors for the development of atrial fibrillation, so it
is not surprising that the incidence of atrialHealth, Inc. All rights reserved.
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FIGURE 1. Pericardial effusions, late-gadolinium enhancement, and native T1 mapping in HIV-infected individuals and
controls. (a) Cine image from a patient with HIV, with arrows demonstrating midwall fibrosis and a small pericardial effusion,
compared with a normal control patient (c). (b) The corresponding T1 map, from a patient with HIV, with associated
pericardial effusion (red) compared with a normal control patient (d). Adapted with permission from [11&&].
Heart failure in persons living with HIV infection Hsue and Watersfibrillation is rising as PLWHIV in the ART era age. In
a national sample of 30533 HIV-infected veterans
followed in the Veterans Affairs HIV Clinical Case
Registry from 1996 to 2011, 780 (2.6%) patients
developed atrial fibrillation during a median fol-
low-up of 6.8 years [13]. Markers of HIV disease
severity, specifically low CD4 count and high viral
load, were independently associated with develop-
ment of atrial fibrillation, as were older age, white
race, coronary disease, heart failure, alcoholism,
proteinuria, reduced kidney function, and hypothy-
roidism.
Drug treatment of atrial fibrillation aims to
control the ventricular rate to preserve exercise
tolerance, and in patients at high risk, to prevent
embolic events. Drugs commonly used for rate con-
trol (digitalis, diltizem, and verapamil) are metabo-
lized by the same hepatic enzyme system as some
forms of ART. Caution is therefore warranted in
dose selection, and a dose adjustment of ART may
be indicated. Scores to assess embolic risk have not
been validated in PLWHIV who have atrial fibrilla-
tion, but recent studies suggest that these throm-
botic risk calculators do not perform well in the
setting of HIV (Chau, K, JAIDS in press). Newer
anticoagulants have not been well studied in
PLWHIV. Atrial fibrillation increases a pill burden Copyright © 2017 Wolters Kluwe
1746-630X Copyright  2017 Wolters Kluwer Health, Inc. All rights resethat may already be onerous and nearly intolerable
for some PLWHIV.TREATMENT OF HEART FAILURE
Treatment recommendations for heart failure in
PLWHIV are based upon trials done in uninfected
heart failure patients and from guidelines based
upon these trials [1]. Thus, angiotensin-converting
enzyme inhibitors, b-blockers, and aldosterone
antagonists should be used, although trials of these
drugs have not been done in PLWHIV with
heart failure.
ART is not specific therapy for heart failure;
however, the incidence of heart failure declined
dramatically after the introduction of ART.Whether
ART can reverse heart failure caused by an estab-
lished cardiomyopathy is not known. On the other
hand, ART drugs such as AZT have direct myocardial
toxicity, and ART may accelerate coronary athero-
sclerosis, ultimately leading to LV dysfunction. The
role of inflammation and immune response in HIV-
associated heart failure is highlighted by a study in
HIV-infected children with LV dilation, in which
better LV contractility was seen in those with higher
endogenous IgG levels and those treated with intra-
venous immunoglobulin [14]. However, in ther Health, Inc. All rights reserved.
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Cardiovascular disease in HIV infected personsabsence of HIV-specific trials, using the same guide-
lines and therapies to treat congestive heart failure
(CHF) among individuals with HIV appears reason-
able. These medications include ACE-inhibitors,
beta blockers, digoxin, aldactone, biventricular
pacemakers, and AICDs. Although many studies
have highlighted echocardiographic abnormalities
in the setting of HIV, the utility of screening asymp-
tomatic individuals with HIV remains uncertain.
Heart transplantation with excellent long-term
survival has been reported in small numbers of HIV-
infected patients [1]. The fear that immunosuppres-
sion in such patients might lead to AIDS has proved
unfounded, and the notion that HIV infection
should be a contraindication to cardiac transplanta-
tion is no longer tenable.PROGNOSIS
HIV-associated cardiomyopathy with heart failure
in the pre-ART era carried a grim prognosis. In one
study, median survival among patients with AIDS
and cardiomyopathy was 101 days compared with
472 among patients with AIDS alone [15]. In anoth-
er study, the adjusted hazard ratio for patients with
cardiomyopathy associated with AIDS was 5.86
compared with patients with idiopathic cardiomy-
opathy [16].
Since the advent of ART, the epidemiology and
prognosis of heart failure in PLWHIV has improved
dramatically. However, symptoms of heart failure or
echocardiographic evidence of cardiomyopathy
greatly increase the risk of death [1]. SCD in HIV
patients occurs at 4.5 times the expected rate, and
systolic and diastolic dysfunction are known to be
present in more than half of such deaths. The pres-
ence of contractile reserve as assessed by dobut-
amine stress echocardiography has been reported
to be a marker for improved survival in HIV patients
with cardiomyopathy. Patients with contractile re-
serve were also more likely to experience an im-
provement in ejection fraction.CONCLUSION
Similar to the uninfected population, heart failure
is becoming increasingly more common among
HIV-infected individuals and is anticipated to in-
crease in clinical significance as this population
ages. Although there are many parallels to the
disease entity of HIV-associated atherosclerosis,
there are relatively fewer studies and less under-
standing of this disease process and even fewer
studies evaluating treatment in the setting of
HIV. Future studies are ongoing to ascertain the
underlying pathophysiology of heart failure in Copyright © 2017 Wolters Kluwer 
538 www.co-hivandaids.comHIV, whichwill be helpful in developing treatment
strategies.
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